Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP03HN106 in Critical Limb Ischemia
NCT06482892Phase 2Completed
- Sponsor
- Talengen Institute of Life Sciences
- Start
- Jul 2024
- Primary completion
- Mar 2026
- Modality
- Biological product
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TP03HN106 in critical limb ischemia (CLI), sponsored by Talengen Institute of Life Sciences. Primary endpoint: Overall clinical treatment efficacy rate at Day 62. Started Jul 2024; status: completed.
02
Drugs
TP03HN106
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT06482892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06482892.